National and Kapodistrian University of Athens
Ο πολυμορφισμός του CYP450 2C19 και επιδράσεις στην λειτουργία του ενδοθηλίου, στην λειτουργικότητα των μεγάλων αγγείων και στην υποκλινική φλεγμονή σε στεφανιαίους ασθενείς
Abstract
dc:descriptionBackground: Coronary artery disease( CAD) is one of the leading causes of death. Dual antiplatelet therapy with aspirin and clopidogrel is the gold standard treatment for CAD. However a significant percentage of patients respond poorly to clopidogrel treatment, a phenomenon known as clopidogrel resistance. The role of CYP2C19*2 polymorphism in plasma clopidogrel active drug metabolite concentrations, in platelet inhibition and in cardiovascular prognosis has been investigated in many studies.Purpose: The evaluation of the impact of functional genetic polymorphism CYP2C19*2 on arterial properties, inflammatory status and clopidogrel resistance in patients with CAD.Methods: We consecutively enrolled 353 patients with stable CAD receiving clopidogrel regimen (75mg/d), at least one month after percutaneous coronary intervention. Endothelial function was evaluated by flow-mediated dilation (FMD) of the brachial artery. Carotid-femoral pulse wave velocity (PWV) was measured as an index of aortic stiffness and augmentation index (AIx) as an index of arterial wave reflections. CYP2C19*2 genotyping was performed by real-time polymerase chain reaction. Serum IL-6, TNF-a and ICAM-1was measured by ELISA. High on treatment platelet reactivity was evaluated using VerifyNow Assay.Results: From the study population 37.6% were carriers of at least one CYP2C19*2 reduced-function allele and 62.4% were non carriers. Importantly, there was no difference in FMD (4.72±2.32% vs. 4.65±2.21% vs. 5.18±2.43%, p=0.11), PWV (8.84±2.11m/sec vs. 8.62±2.24m/sec vs. 9.01±2.48m/sec, p=0.11) , AIx values (25.42±8.30% vs. 23.9±11.02% vs. 22.82±5.84, p=0.08) and ICAM-1(5.62±0.35ng/ml vs 5.55±0.48ng/ml, p=0.456), TNF-a (0.67±0.79 pg/ml vs 0.73±0.69 pg/ml vs 0.40±0.21 pg/ml, p=0.666), IL-6(1.04±0.91pg/ml vs 0.96±0.75pg/ml vs 1.01±0.87 pg/ml, p=0,816) between carriers and non carriers respectively. Patients with increased PRU demonstrated elevated values of PWV (8.81±2.25 m/sec vs. 7.69±1.95 m/sec, p=0.001), Aix (25.27±8.67 % vs. 20.87±10.57 %, p=0.04) and FMD (4.57± 1.97% vs 6.77±3,35%, p=0.005) . Finally, carriers of two CYP2C19*2 reduced-function allele had significantly increased PRU (292±53 vs. 198±83, p=0.007).Conclusion: The presence of CYP2C19*2 loss of action polymorphism displays no impact on arterial wall properties in patients with CAD treated with clopidogrel regimen. Both CYP2C19*2 and HPR are associated with recurrent cardiovascular events. Increased HPR is associated with impaired arterial stiffness and endothelial function in patients after percutaneous coronary intervention receiving clopidogrel treatment, highlighting another clinical factor implicated in individual platelet response to antiplatelet therapy.Η περίληψη να περιλαμβάνει τον στόχο, τη μεθοδολογία και τα αποτελέσματα - συμπεράσματα της διατριβής. Συστήνεται να είναι έως 2.500 χαρακτήρες μαζί με τα κενά ή ~450 λέξεις.
Degree
thesis:*- Grantor dc:publisher
- National and Kapodistrian University of Athens
- Year dc:date
- 2014
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Zaromytidou, Marina
- Ζαρομυτίδου, Μαρίνα
Subjects
dc:subject × 16- Πολυμορφισμός CYP2C19*2
- Ενδοθηλιακή λειτουργία
- Αρτηριακή σκληρία
- Κλοπιδογρέλη
- Στεφανιαία νόσος
- CYP2C19*2 polymorphism
- Endothelial dysfunction
- Arterial stiffness
- Clopidogrel
- Coronary artery disease
- Ιατρική και Επιστήμες Υγείας
- Βασική Ιατρική
- Κλινική Ιατρική
- Medical and Health Sciences
- Basic Medicine
- Clinical Medicine
Rights
dc:rights- Statement dc:rights
-
- BY_NC_SA
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/42209